Antibody to carcinoembryonic antigen data

Investigators presented results of a Phase I trial in patients with advanced drug-refractive disease. As discussed at the American Society of Clinical Oncology meeting in Philadelphia, an antibody to CEA labeled with I-131 was able to target 34 of 36 sites of known disease in 11 patients. Of the 9 patients assessable for anti-tumor response in the dose escalating trial, one with diffuse peritoneal implants of <2 cm had a complete clinical remission for eight months, following an initial partial remission for 10 months. ...